2315
HKSE:2315
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Stock
Last Close
6.11
25/09 08:08
Market Cap
3.05B
Beta: -
Volume Today
688K
Avg: 161.05K
PE Ratio
−7.72
PFCF: −5.73
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|
average inventory | 11.56M - | 55.12M 376.83% | 51.26M 7.01% | ||
average payables | 95.02M - | 124.32M 30.83% | 160.71M 29.28% | ||
average receivables | 180.15M - | 180.47M 0.18% | 139.41M 22.76% | ||
book value per share | 3.66 - | 3.14 14.19% | 1.90 39.43% | 1.97 3.61% | |
capex per share | -0.77 - | -0.50 35.16% | -0.40 20.17% | ||
capex to depreciation | -7.07 - | -1.55 78.05% | -1.38 10.87% | ||
capex to operating cash flow | 1.36 - | 0.54 60.06% | 0.79 46.11% | ||
capex to revenue | -1.21 - | -0.56 53.64% | -0.45 19.55% | ||
cash per share | 2.39 - | 1.43 40.38% | 1.02 28.88% | 1.07 5.35% | |
days of inventory on hand | 33.65 - | 51.59 53.30% | 244.23 373.40% | 13.14 94.62% | |
days payables outstanding | 369.43 - | 349.07 5.51% | 375.42 7.55% | 310.49 17.30% | |
days sales outstanding | 195.45 - | 231.14 18.26% | 93.27 59.65% | 72.49 22.28% | |
debt to assets | 0.20 - | 0.23 17.27% | 0.15 36.56% | 0.21 42.51% | |
debt to equity | 0.32 - | 0.43 35.27% | 0.36 16.07% | 0.66 81.84% | |
dividend yield | |||||
earnings yield | -0.06 - | -0.07 11.05% | -0.04 37.14% | -0.09 115.50% | |
enterprise value | 8.38B - | 8.49B 1.29% | 13.58B 59.99% | 4.16B 69.34% | |
enterprise value over ebitda | -26.32 - | -22.49 14.56% | -32.86 46.14% | -41.02 24.81% | |
ev to operating cash flow | -37.20 - | -23.21 37.61% | -44.79 92.97% | -54.33 21.30% | |
ev to sales | 33.06 - | 23.94 27.57% | 25.44 6.25% | 5.81 77.17% | |
free cash flow per share | -1.34 - | -1.42 6.15% | -0.90 36.49% | -0.19 78.71% | |
free cash flow yield | -0.06 - | -0.07 9.30% | -0.04 41.09% | -0.02 52.25% | |
graham net net | 0.47 - | -0.78 264.41% | -1.48 89.72% | -2.82 91.03% | |
graham number | 10.62 - | 10.22 3.80% | 6.55 35.93% | 6.53 0.21% | |
income quality | 0.47 - | 0.67 41.83% | 0.50 24.77% | 0.20 60.31% | |
intangibles to total assets | 0.00 - | 0.00 151.95% | 0.01 316.36% | 0.01 4.90% | |
interest coverage | -16.87 - | -13.33 21.01% | -10.79 19.01% | ||
interest debt per share | 1.23 - | 1.46 18.80% | 0.78 46.23% | 1.30 65.97% | |
inventory turnover | 10.85 - | 7.07 34.77% | 1.49 78.88% | 27.78 1,758.64% | |
invested capital | 0.32 - | 0.43 35.27% | 0.36 16.07% | 0.66 81.84% | |
market cap | 8.67B - | 8.42B 2.88% | 13.77B 63.59% | 4.06B 70.49% | |
net current asset value | 279.36M - | -176.57M 163.21% | -729.72M 313.27% | -935.92M 28.26% | |
net debt to ebitda | 0.90 - | -0.19 121.19% | 0.45 338.54% | -0.99 316.99% | |
net income per share | -1.37 - | -1.48 7.85% | -1.00 32.24% | -0.96 3.89% | |
operating cash flow per share | -0.57 - | -0.92 62.34% | -0.50 45.36% | -0.19 61.81% | |
payables turnover | 0.99 - | 1.05 5.83% | 0.97 7.02% | 1.18 20.91% | |
receivables turnover | 1.87 - | 1.58 15.44% | 3.91 147.81% | 5.04 28.67% | |
research and ddevelopement to revenue | 1.09 - | 1.58 44.54% | 1.31 16.86% | 0.66 49.47% | |
return on tangible assets | -0.23 - | -0.25 9.14% | -0.22 14.72% | -0.16 27.27% | |
revenue per share | 0.64 - | 0.89 39.84% | 0.89 0.77% | 1.80 102.93% | |
roe | -0.37 - | -0.47 25.68% | -0.53 11.88% | -0.49 7.24% | |
roic | -0.22 - | -0.30 38.72% | -0.34 12.24% | -0.23 33.26% | |
sales general and administrative to revenue | 0.21 - | 0.20 4.81% | 0.49 141.18% | 0.40 19.07% | |
shareholders equity per share | 3.66 - | 3.14 14.19% | 1.90 39.43% | 1.97 3.61% | |
stock based compensation to revenue | 0.52 - | 0.08 85.02% | 0.03 63.36% | 0.04 50.64% | |
tangible asset value | 1.46B - | 1.25B 14.42% | 1.12B 10.09% | 762.31M 31.95% | |
tangible book value per share | 3.67 - | 3.14 14.42% | 1.86 40.75% | 1.91 2.84% | |
working capital | 819.17M - | 427.68M 47.79% | 313.25M 26.76% | 145.43M 53.57% |
All numbers in HKD (except ratios and percentages)